Mali

• 

  Subject Areas on Research

  • A 19-year retrospective investigation of maternal mortality at Point G National Hospital, Bamako, Mali. 
  • A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy. 
  • A comparison of anemia in hemoglobin C and normal hemoglobin A children with Plasmodium falciparum malaria. 
  • A deep sequencing approach to estimate Plasmodium falciparum complexity of infection (COI) and explore apical membrane antigen 1 diversity. 
  • A severe symptom phenotype in tomato in Mali is caused by a reassortant between a novel recombinant begomovirus (Tomato yellow leaf curl Mali virus) and a betasatellite. 
  • A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. 
  • Antibodies to Peptides in Semiconserved Domains of RIFINs and STEVORs Correlate with Malaria Exposure. 
  • Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. 
  • Association of HLA alleles with Plasmodium falciparum severity in Malian children. 
  • Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children. 
  • Association of intraleukocytic Plasmodium falciparum malaria pigment with disease severity, clinical manifestations, and prognosis in severe malaria. 
  • Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy. 
  • Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. 
  • Community permission for medical research in developing countries. 
  • Differential recognition of terminal extracellular Plasmodium falciparum VAR2CSA domains by sera from multigravid, malaria-exposed Malian women. 
  • Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. 
  • Effect of red blood cell variants on childhood malaria in Mali: a prospective cohort study. 
  • Effects of concomitant Schistosoma haematobium infection on the serum cytokine levels elicited by acute Plasmodium falciparum malaria infection in Malian children. 
  • Erythrocyte CR1 expression level does not correlate with a HindIII restriction fragment length polymorphism in Africans; implications for studies on malaria susceptibility. 
  • Expression of complement and toll-like receptor pathway genes is associated with malaria severity in Mali: a pilot case control study. 
  • Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. 
  • Extent and Dynamics of Polymorphism in the Malaria Vaccine Candidate Plasmodium falciparum Reticulocyte-Binding Protein Homologue-5 in Kalifabougou, Mali. 
  • Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. 
  • HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. 
  • Hemoglobin C Trait Provides Protection From Clinical Falciparum Malaria in Malian Children. 
  • Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. 
  • Identification of the Kna/Knb polymorphism and a method for Knops genotyping. 
  • Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02A. 
  • Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. 
  • Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. 
  • Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali. 
  • Low multiplication rates of African Plasmodium falciparum isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulence. 
  • Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. 
  • Maternal and neonatal outcomes of grand multiparas over two decades in Mali. 
  • Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. 
  • New var reconstruction algorithm exposes high var sequence diversity in a single geographic location in Mali. 
  • Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. 
  • No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. 
  • Parasite clearance following treatment with sulphadoxine-pyrimethamine for intermittent preventive treatment in Burkina-Faso and Mali: 42-day in vivo follow-up study. 
  • Plasmodium vivax Infections over 3 Years in Duffy Blood Group Negative Malians in Bandiagara, Mali. 
  • Platelet-mediated clumping of Plasmodium falciparum infected erythrocytes is associated with high parasitemia but not severe clinical manifestations of malaria in African children. 
  • Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara, Mali. 
  • Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. 
  • Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis. 
  • Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. 
  • Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. 
  • Serum antibody levels to glycosylphosphatidylinositols in specimens derived from matched Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. 
  • Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. 
  • Short report: rare Plasmodium falciparum merozoite surface protein 1 19-kda (msp-1(19)) haplotypes identified in Mali using high-throughput genotyping methods. 
  • Spatio-Temporal Dynamics of Asymptomatic Malaria: Bridging the Gap Between Annual Malaria Resurgences in a Sahelian Environment. 
  • Spatio-temporal analysis of malaria within a transmission season in Bandiagara, Mali. 
  • Stable malaria incidence despite scaling up control strategies in a malaria vaccine-testing site in Mali. 
  • Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine. 
  • Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate. 
  • Two complement receptor one alleles have opposing associations with cerebral malaria and interact with α+thalassaemia. 
  • Use of antimalarial drugs in Mali: policy versus reality. 
  • [In vitro cultivation of fields isolates of Plasmodium falciparum in Mali].